|Congrats on a Potential 40%+ in Bookable Gains Yesterday on BCAN. We Opened at $3.50 and Closed at $5.03/Share. Currently at $4.20/Share After Some Profit Taking.
It’s Time to Revisit a Biopharma Company That has Big Catalysts Lined Up
A Look at Comments by Fed Chair Powell
Good day everyone,
Fed chairman Powell made comments this week that may indicate that the Fed is easing its stance on raising interest rates but remains unconvinced that inflation has been handled:
Powell said, “The time for moderating the pace of rate increases may come as soon as the December meeting.”
“By any standard, inflation remains much too high,” said Powell. “It will take substantially more evidence to give comfort that inflation is actually declining.”
The House on Wednesday approved legislation to avert a rail shutdown that could be costly to the economy and inconvenient for those who commute by rail. The bill will now go to the Senate, and I note that Congress has voted to stop or end rail strikes every time going back to the 1960s.
I want to update you on a NASDAQ listed company in the biopharma sector. Sometimes I alert you to companies that have an upcoming potential catalyst, but in this case, I’m planning to cover a long list of potential catalysts. The moves this company made in H2 this year look like they might propel this company into massive revenue gains in 2023.
I like the stats this company has as well. Small share structure, cash in the bank, big insider ownership position and a sizeable investment from institutions. You might appreciate that this company is operating with several revenue streams, so all their eggs aren’t in one basket.
Stay tuned and stay informed. We will issue this report on Friday, December 2, 2022, at or near the market open.
The Traders News Source